NASDAQ:CAPS Capstone Therapeutics Q2 2025 Earnings Report $1.02 -0.08 (-7.27%) As of 10/17/2025 04:00 PM Eastern ProfileEarnings HistoryForecast Capstone Therapeutics EPS ResultsActual EPS-$0.13Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ACapstone Therapeutics Revenue ResultsActual Revenue$12.85 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ACapstone Therapeutics Announcement DetailsQuarterQ2 2025Date8/15/2025TimeBefore Market OpensConference Call DateFriday, August 15, 2025Conference Call Time7:00AM ETConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Capstone Therapeutics Earnings HeadlinesMichael ParkerJune 18, 2025 | latimes.comCapstone Holding Corp., Secures $1 Million Pangaea Stone Order in Expanding TerritoryJune 17, 2025 | finanznachrichten.deTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes. | Porter & Company (Ad)Pinecrest, Florida Resident David Buitrago Completes Intensive Capstone Research ProjectJune 16, 2025 | msn.comA capstone projectJune 14, 2025 | yahoo.comCSM Honors 32 Leaders in 2025 Academy CeremonyJune 14, 2025 | msn.comSee More Capstone Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Capstone Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Capstone Therapeutics and other key companies, straight to your email. Email Address About Capstone TherapeuticsCapstone Therapeutics (NASDAQ:CAPS), a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona.View Capstone Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Goldman Sachs Earnings Tell: Markets Seem OkayWhy Congress Is Buying Intuitive Surgical Ahead of Earnings3 Reasons to Buy Sprouts Farmers Market Ahead of EarningsTesla Earnings Loom: Bulls Eye $600, Bears Warn of $300Spotify Could Surge Higher—Here’s the Hidden Earnings SignalBerkshire-Backed Lennar Slides After Weak Q3 EarningsWall Street Eyes +30% Upside in Synopsys After Huge Earnings Fall Upcoming Earnings Intuitive Surgical (10/21/2025)Nasdaq (10/21/2025)Netflix (10/21/2025)Texas Instruments (10/21/2025)Citigroup (10/21/2025)Chubb (10/21/2025)Capital One Financial (10/21/2025)Danaher (10/21/2025)Elevance Health (10/21/2025)GE Aerospace (10/21/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
